D-0926-2017 Class III Terminated
FDA drug recall D-0926-2017 was initiated by Sanofi-Aventis U.S. LLC on Jun 12, 2017 and is designated Class III. Reason for recall: Superpotent Drug: high out-of-specification result for magnesium. The recall status is terminated (terminated Feb 7, 2019). Affected quantity: 2980 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jul 5, 2017
- Initiation Date
- Jun 12, 2017
- Termination Date
- Feb 7, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 2980 bottles
Product description
Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distributed by: GlaxoSmithKline Consumer Healthcare, L.P., Moon Twp, PA 15108, UPC 3 0088-1175-47 8.
Reason for recall
Superpotent Drug: high out-of-specification result for magnesium.
Distribution pattern
Nationwide in the USA, Puerto Rico, and the United Kingdom.
Code information
Lot #: 5J69A, Exp 02/19; 6GF2A, 6GF3A, Exp 08/19
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0926-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026